<DOC>
	<DOCNO>NCT02459353</DOCNO>
	<brief_summary>Dapagliflozin improve glycemic variability subject type 2 diabetes mellitus add insulin therapy . The primary objective study assess effect dapagliflozin glucose variability compare placebo 12 week treatment type 2 diabetic patient inadequate glycemic control insulin .</brief_summary>
	<brief_title>Effect Dapagliflozin Glycemic Variability</brief_title>
	<detailed_description>This study multicenter , randomize , double-blind , placebo-controlled phase 4 study evaluate whether treatment dapagliflozin add-on insulin reduces glucose variability type 2 Diabetes Mellitus . The study recruit type 2 Diabetes Mellitus patient inadequate glucose control insulin treatment without metformin sulphonylurea . It estimate 90 type 2 diabetic patient enrol . After randomization , total 12 week treatment dapagliflozin match placebo administer . Before treatment , test efficacy safety outcome perform .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Female male age 20~70 year 2 . Type 2 diabetes patient 3 . Treatment basal insulin therapy ≥0.2U/kg/day ( ±metformin and/or ±sulfonylurea ) least 12 week 4 . Inadequate glycemic control ; HbA1c 7.0 % ~10.0 % screen 5 . Female childbearing potential agrees routinely use adequate contraception signing inform consent throughout duration study 6 . Understands study procedure , alternative , risk voluntarily agree participated give write informed consent 1 . Type 1 diabetes ( Fasting Cpeptide ≤ 0.78ng/dL ( 0.26 nM/L ) ) , secondary diabetes , gestational diabetes 2 . Insulin therapy modality contain short rapid act insulin ( continuous subcutaneous insulin injection , premixed insulin , basalbolus insulin ) 3 . History diabetic ketoacidosis , hyperglycemic hyperosmolar state 4 . Estimated glomerular filtration rate &lt; 60 mL/min/1.73 m2 5 . History chronic cystitis recurrent urinary tract infection 6 . Currently loop diuretic 7 . Adrenal insufficiency , pituitary insufficiency 8 . Currently medication know affect glucose metabolism ( e.g . corticosteroid , immunosuppressant ) 9 . Hemoglobin &lt; 10g/dL female , &lt; 12g/dL male 10 . Abnormal liver function ( AST/ALT &gt; x3 upper normal limit ) 11 . On weight loss program take weight loss medication 12 . NYHA class III , IV congestive heart failure 13 . History acute myocardial infarction , unstable angina , coronary artery bypass graft stroke within 6 month 14 . History bladder cancer 15 . History malignancy within 5 year 16 . Pregnant lactate woman 17 . History excessive alcohol abuse ( ≥30g/day ) 18 . Hypersensitivity SGLT2 inhibitor 19 . Patient rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . 20 . Subject investigator deems inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>dapagliflozin</keyword>
	<keyword>glucose variability</keyword>
</DOC>